Company intelligence

IMTX

Immatics N.V. · NASDAQ · Healthcare

Price$9.24+6.33% · +$0.55

Market cap1.24BEquity value

P / E-5.0Trailing ratio

Volume1.06MLatest session

Market data

IMTX price chart

TradingView

Related signals

1 min delayed

Browse public IMTX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

IMTXOct 10, 2024-5.03% since signal

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics N.V. initiated a $150 million public offering. Updated Phase 1b data shows IMA203 effective in melanoma patients. No Grade 5 adverse events reported in IMA203 treatment. Approximately 50% of Phase 1b patients achieved over 50% tumor reduction. Phase 3 trial for IMA203 is set to start in December 2024.

View signal analysis

Research